Why Is Accelerant Going Private Just One Year After Its IPO?

Accelerant Holdings ARX, which went public just over a year ago, recently agreed to be acquired by Thoma Bravo and become a privately held company. The all-cash deal carries an enterprise value of more than $4 billion. Shares of the company jumped nearly 44% following the announcement on Aug. 13, 2026.

Accelerant priced its IPO at $21 per share in July 2025. But the stock subsequently struggled and traded well below the IPO price, reaching as low as about $9.18 earlier in 2026. Investor concerns regarding its complicated insurance structure and AI-driven disruption potential weighed on the stock. According to the new deal, Class A and Class B shareholders will receive $20.25 in cash for each share, a 49% premium to the Aug. 12 price, but still slightly below ARX's original IPO price.

Meanwhile, the underlying business was improving, creating a notable disconnect between operating performance and the stock’s valuation. In second-quarter 2026, revenues reached $356.9 million, up 62.9% year over year, while net income jumped to $80 million from $13.1 million. Adjusted EBITDA rose to $93.1 million, and Exchange Written Premium increased 23% to $1.32 billion. Against that backdrop, the acquisition offer gives shareholders an opportunity to exit at a substantial premium while still valuing ARX below its IPO price.

Accelerant’s independent Special Committee recommended the transaction, and the board approved it unanimously. The deal is expected to be closed in the first half of 2027. Altamont Capital Partners, which holds about 82% of voting rights, has agreed to support the transaction and retain some equity ownership alongside Thoma Bravo.

For the acquirer, the deal provides a way to back Accelerant’s data-driven specialty insurance marketplace and invest further in its technology, data and capital capacity. The agreement also removes public-market pressure while giving management more room to focus on long-term growth opportunities.

ARX’s Price Performance

Accelerant shares have gained 19.7% year to date, thanks to the jump following the acquisition announcement, against the industry’s 3.8% decline.

Image Source: Zacks Investment Research

Zacks Rank & Other Key Picks

Accelerant currently has a Zacks Rank #2 (Buy). Some other top-ranked stocks in the broader Finance space are CNO Financial Group, Inc. CNO, Horace Mann Educators Corporation HMN and Ategrity Specialty Insurance Company Holdings ASIC, each carrying a Zacks Rank #2 at present as well. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Zacks Consensus Estimate for CNO Financial’s current-year earnings is pegged at $4.74 per share, which indicates 16.2% year-over-year growth. It has witnessed two upward estimate revisions against none in the opposite direction in the past 30 days. CNO beat earnings estimates in each of the last four quarters, with an average surprise of 23.2%.

The consensus mark for Horace Mann Educators’ current-year earnings is pegged at $4.78 per share, which has witnessed two upward revisions over the past 30 days and no movement in the opposite direction. Furthermore, the consensus estimate for HMN’s 2026 revenues indicates a 3.9% year-over-year increase.

The Zacks Consensus Estimate for Ategrity Specialty’s current year earnings is pegged at $2.16 per share, which indicates 34.2% year-over-year growth. It has witnessed one upward estimate revision against none in the opposite direction in the past month. ASIC beat earnings estimates in the last four quarters, with an average surprise of 30.2%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research